Aortic Stenosis Clinical Trial
Official title:
The Plasma Serotonin and Aortic Stenosis: a Pilot Study.
The goal of this study is to describe the increase in plasma serotonin or 5-hydroxytryptamine (5-HT) in patient with increased severity of aortic stenosis and increased weight cardiac muscle.
Calcific aortic stenosis is the most frequent valve disease in adults. Without therapeutic
strategy, this disease leads to heart failure and death. Surgical aortic valve replacement
is now a well tolerated cardiac surgery leading to excellent outcomes. Until recently,
calcific aortic stenosis was considered to be histopathologically degenerative or passive in
origin. It is now recognized, however, as a complex cellular process with features of
atherosclerosis. It has been observed that drugs may slow dawn the progression of aortic
stenosis in observational studies.
It has been suggested that serotonin, a monoamine neurotransmitter and a peripheral signal
mediator, may be involved in the progression of aortic stenosis and also in its consequences
on myocardium hypertrophy.
In the blood, serotonin in mainly stored in platelets, which release serotonin involved in
post-injury vasoconstriction, thrombus formation, fibrosis and atherogenesis.
This study hypothesized those patients with aortic stenosis exhibit higher circulating
serotonin levels than their counterparts without heart disease. In addition to circulating
serotonin, its metabolite 5-HIAA will be systematically measured on all patients.
This study would allow to determine the potential of plasma serotonin as a prognosis marker
and perhaps suggest the discovery of new targets for treatment of aortic stenosis.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04310046 -
Optimal Timing of Transcatheter Aortic Valve Implantation and Percutaneous Coronary Intervention - The TAVI PCI Trial
|
N/A | |
Completed |
NCT03332745 -
Mechanism of Decompensation Evaluation - Aortic Stenosis
|
||
Recruiting |
NCT06008080 -
Post-Market Clinical Follow Up Study With Navitor Valve
|
||
Recruiting |
NCT06055751 -
Long Term Evaluation of Cardiac Arrhythmias After Transcatheter Aortic Valve Implantation -The LOCATE Registry
|
||
Active, not recruiting |
NCT04815785 -
Safety and Efficacy of TaurusOne® Transcatheter Aortic Valve System in Patients With Severe Calcific Aortic Stenosis
|
N/A | |
Terminated |
NCT02202434 -
Safety and Efficacy Study of Lotus Valve for Transcatheter Aortic Valve Replacement
|
N/A | |
Recruiting |
NCT03029026 -
The Role of Occult Cardiac Amyloid in the Elderly With Aortic Stenosis.
|
||
Active, not recruiting |
NCT02903420 -
A Clinical Trial of Transcatheter Aortic Valves in Dialysis Patients (Japan)
|
N/A | |
Completed |
NCT02629328 -
CardioCel Tri-leaflet Repair Study
|
N/A | |
Completed |
NCT02306226 -
Symetis ACURATE Neo™ Valve Implantation SAVI TF Registry
|
||
Completed |
NCT01676727 -
ADVANCE Direct Aortic Study
|
||
Withdrawn |
NCT01648309 -
Neuropsychological Testing in Patients Undergoing Transvascular Aortic Valve Implantation
|
N/A | |
Completed |
NCT01422044 -
Risk Prediction in Aortic Stenosis
|
N/A | |
Withdrawn |
NCT00774657 -
Ventricular Remodeling In Patients With Aortic Stenosis Assessed Echocardiography
|
N/A | |
Terminated |
NCT00535899 -
Speckle Tracking Imaging in Patients With Low Ejection Fraction Aortic Stenosis (SPArKLE-AS)
|
N/A | |
Terminated |
NCT05070130 -
OpSens PRIME CLASS
|
||
Completed |
NCT03314857 -
China XT: Safety and Effectiveness of Edwards Lifesciences SAPIEN XT THV in the Chinese Population
|
N/A | |
Completed |
NCT04157920 -
Impact of Predilatation Between Self-expanding Valves
|
N/A | |
Enrolling by invitation |
NCT06212050 -
Feasibility, Safety, and Effectiveness of the ACURATE neo2 Transcatheter Heart Valve for Severe Bicuspid Aortic Stenosis
|
||
Recruiting |
NCT05893082 -
Multicenter Feasibility Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR
|
N/A |